LOBEF (Lobe Sciences) Total Receivables: $0.02 Mil (As of Feb. 2026)


What is Lobe Sciences Total Receivables?

Lobe Sciences LOBEF +12.45% Total Receivables is $0.02 Mil as of Feb. 2026. The stock has 2 warning signs investors should review.

Lobe Sciences's Total Receivables for the quarter that ended in Feb. 2026 was $0.02 Mil.

Lobe Sciences Total Receivables Related Terms

Lobe Sciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Total Receivables Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 0.01 0.01 0.01 0.04

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.04 0.01 0.02

Lobe Sciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.02 Mil mean?
Lobe Sciences (LOBEF) has a Total Receivables of $0.02 Mil as of Feb. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lobe Sciences and its competitors.
Is Lobe Sciences' Total Receivables too high?
Lobe Sciences' current Total Receivables is $0.02 Mil.
How does Lobe Sciences' Total Receivables compare to VRTX and REGN?
Lobe Sciences' Total Receivables of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current Total Receivables is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Total Receivables of $0.02 Mil. The current Total Receivables is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Total Receivables is $0.02 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.